Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease

Kiyohiko Izumi; Kozo Morimoto; Kazuhiro Uchimura; Manabu Ato; Naoki Hasegawa; Satoshi Mitarai

doi:10.1183/23120541.00097-2019

Tables

TABLE 1

The demographic and clinical factors associated with nonstandard treatment

Variable	Total patients with standard and nonstandard treatment (N=15 431)	Patients with nonstandard treatment (N=8460)	Univariate analysis		Multivariate analysis
Variable		Patients with nonstandard treatment (N=8460)	OR (95% CI)	p-value	aOR (95% CI)	p-value
Sex
Males	4197	2359 (56.2%)	Ref.		Ref.
Females	11 234	6101 (54.3%)	0.93 (0.86–0.99)	0.035	0.98 (0.91–1.06)	0.640
Age years
40–49	520	209 (40.2%)	Ref.		Ref.
50–59	1798	816 (45.4%)	1.24 (1.01–1.51)	0.036	1.23 (1.01–1.5)	0.044
60–69	4444	2188 (49.2%)	1.44 (1.2–1.74)	<0.001	1.42 (1.18–1.71)	<0.001
70–79	5568	3162 (56.8%)	1.96 (1.63–2.35)	<0.001	1.92 (1.6–2.31)	<0.001
≥80	3101	2085 (67.2%)	3.05 (2.52–3.7)	<0.001	3.01 (2.49–3.65)	<0.001
Comorbidity
Rheumatoid arthritis
No	13 998	7591 (54.2%)	Ref.		Ref.
Yes	1433	869 (60.6%)	1.30 (1.16–1.45)	<0.001	1.36 (1.21–1.53)	<0.001
Bronchiectasis
No	11 664	6380 (54.7%)	Ref.		Ref.
Yes	3767	2080 (55.2%)	1.02 (0.95–1.1)	0.579	1.02 (0.95–1.1)	0.618
COPD
No	14 350	7783 (54.2%)	Ref.		Ref.
Yes	1081	677 (62.6%)	1.41 (1.24–1.61)	<0.001	1.31 (1.14–1.49)	<0.001
Sequelae of pulmonary TB
No	14 628	7988 (54.6%)	Ref.		Ref.
Yes	803	472 (58.8%)	1.19 (1.03–1.37)	0.021	1.02 (0.88–1.18)	0.828
Interstitial pneumonia
No	14 038	7655 (54.5%)	Ref.		Ref.
Yes	1393	805 (57.8%)	1.14 (1.02–1.28)	0.020	1.02 (0.91–1.15)	0.732

Patients who did not receive treatment were excluded from the regression analysis. International Classification of Diseases 10 codes for aspergillosis (B487, B449 and B441), rheumatoid arthritis (M0510, M0530, M0590, M0600, M0690, M0691, M0692, M0693, M0694, M0695, M0696, M0697, M0698 and M0800), bronchiectasis (J47, A162 and Q334), COPD (J449), sequelae of pulmonary tuberculosis (TB) (B909), lung cancer (C340, C341, C342, C343, C349, C780, C795 and Z122), interstitial pneumonia (J704, J841, J849, M0510, M330, M321, M332 and M351) and diabetes mellitus (E10 and E11). To ensure the specificity of comorbidities, a comorbidity was identified when at least five associated claims were made. aOR: adjusted odds ratio; Ref.: reference. p<0.05 was considered statistically significant.